The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Jon Young - Canaccord Genuity Group Inc - Analyst
: Good morning and thanks for taking the question and congratulations on the quarter. I think I want to start on the guidance you put out for next
year, especially on the MedTech with the 10% to 12% growth. I'd be interested to hear about the methodology you came up with that, especially
when it comes to the prostate indication. Have you baked in any benefit from that prostate indication for a second fiscal '25?
Question: Jon Young - Canaccord Genuity Group Inc - Analyst
: I appreciate all that color. That's very helpful. And maybe just turning towards back to me. Especially as we talk about next year too, the new product
initiatives that you mentioned on the call. Are these more ancillary products, our ideas and improvements to the existing AlphaVac products? And
then also just with the from the IP litigation that's pops up in this space of the past few months? What is your comfort around frame to operate
with the current AlphaVac? Thank you again.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JULY 16, 2024 / 12:00PM, ANGO.OQ - Q4 2024 AngioDynamics Inc Earnings Call
Question: Jon Young - Canaccord Genuity Group Inc - Analyst
: Great. Thank you again.
Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst
: Thank you. Good morning, guys. I guess also on mechanical thrombectomy, great to see the AngioVac stability. Can you talk a little bit more about
what's driving that? What some of the efforts you've been putting forth to kind of keep that stable while off of that ramps? And what's your visibility
like on maintaining that stability here in FY '25?
Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst
: And then and then just on AlphaVac PE, have you moved into full launch yet? Or can you talk a little bit more about sort of the ramp of the full
launch here this year?
Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst
: And then just shifting to NanoKnife, can you talk a bit more about the reimbursement efforts around pricing that you mentioned what are you
looking to achieve there? And when could that happen potentially? And it sounds like you think the benefits of the preserve data and label can
certainly start before any of that on the reimbursement front?
Question: Steven Lichtman - Oppenheimer & Co., Inc. - Analyst
: That's great. Thanks, guys.
Question: Yi Chen - H.C. Wainwright., LLC - Analyst
: Thank you for taking my questions. Could you comment on if there is any difference in commercial strategies between the US and Europe for
AlphaVac for PE indication? And what is the expected impact on operating expenses? Thank you.
Question: Yi Chen - H.C. Wainwright., LLC - Analyst
: Got it. Could you also give us some specifics on the prostate patient population that are suitable to see NanoKnife treatment?
Question: Yi Chen - H.C. Wainwright., LLC - Analyst
: Got it. Thank you.
| 
